MERS-CoV NSP16 necessary for IFN resistance and viral pathogenesis
V. D. Menachery, L. E. Gralinski, H. D. Mitchell, K. H. Dinnon, S. R. Leist, B. L. Yount, R. L. Graham, E. T. McAnarney, K. G. Stratton, A. S. Cockrell, K. Debbink, A. C. Sims, K. M. Waters, R. S. Baric
This study shows that disrupting MERS-CoV NSP16's 2O methyl-transferase activity attenuates viral pathogenesis and provides a live attenuated vaccine platform.
bioRxiv · Aug 8, 2017Microbiology